NYSE · IQV · Diagnostics & Research
IQVIA Holdings, Inc. (IQV) stock analysis
- IQV gained 2.4% over the past month versus 0.0% for the S&P 500, ranking 259th of 497 S&P 500 stocks.
- Over 12 months it returned +30.5%, 14.7 points ahead of the S&P 500, and trades 0.0% below its 52-week high.
- In the last 30 days 0 analysts raised earnings estimates and 4 cut; forward EPS moved −0.3% (+1.8% over 90 days).
- It sits in the Clinical research outsourcing segment of the Healthcare Value Chain, where the 1-month median return is +8.0%.
- The daily chart reads Intermediate uptrend · Trend advance (since Oct 21, 2026).
One-year price with 50- and 200-day averages
Performance vs the market
Total price return against the S&P 500 (SPY) and the median of US stocks in the same sector.
Chart structure
Read by our daily-bar structure engine from swing highs, swing lows and moving averages.
Holding since Oct 21, 2026
- Close above EMA20 above EMA50
- EMA50 rose over the last ten sessions
- Some swings conflict with the averages
89 occurrences in 10 years. The median move over the next 20 sessions was +0.2%, positive 51% of the time, against +1.3% for any day in the same period.
Analyst earnings revisions
Changes to the consensus forward-EPS estimate. Rising estimates mean analysts see more profit ahead.
19 analysts cover the stock
Where it sits in the supply chain
Healthcare Value Chain · Tools & research
Drug makers outsource clinical trials and data services; new bookings lead pipeline progress.
Also on: Medtech, Diagnostics & Care
Figures are each company's 1-month return; the segment shows its median · Doubler daily batch · company chain maps
Risk profile
Track this stock every day
Hub adds the daily brief, StockFlow factor flow, trade plans and alerts for your watchlist.